Clinerion Adds RWD RADAR to Patient Network Explorer
RWD RADAR generates patient cohort aggregate metrics, as well as offers metrics on the patient journey, from diagnosis to treatment modalities, and geographically, all based on real-world data available on Clinerion’s Patient Network Explorer platform. Patient cohort aggregate metrics show insights on disease-treatment relationships and disease-disease relationships, and are visualized as Top N lists, ranking the related concepts within a field code with the highest patient hits.
The statistics are based on real-time data and available with timestamps, allowing the generation of an incidence timeline. Data may be visualized aggregated, or geographically mapped, as well as showing gender and age distributions.
RWD RADAR can be used for epidemiology studies to look at disease occurrence, treatment metrics, differences by hospital, region, and country, as well as to identify differential treatment groups or cohorts by location, procedure or medication (segmentation by different treatment options and/or by drug/drug class).
Further developments under development by Clinerion include the installation of an infrastructure for deployment of artificial intelligence / machine learning algorithms.
For more information, click here.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
